Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZ13754366
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AZ13754366 is a radiolabeled compound used as a **positron emission tomography (PET) radioligand**. In clinical research, [11C]AZ13754366 enables visualization and measurement of muscarinic receptor occupancy in human lungs, primarily for the basic science investigation of inhaled muscarinic antagonists, such as AZD2115 and tiotropium. It is not a therapeutic agent itself and does not have direct disease-modifying or pharmacological activity, but serves as an imaging tool in early-phase clinical trials.
- Other names
- [11C]AZ13754366
02
Targets
mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on AZ13754366.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZ13754366.